Neurothera Labs Inc. is a clinical-stage pharmaceutical company headquartered in Vancouver, Canada, focused on developing novel therapeutics for central nervous system disorders and other underserved health conditions. The company develops drug programs based on cannabinoid compounds, including SCI-110 for treating Tourette syndrome and Alzheimer's disease-related agitation, and SCI-210 for autism spectrum disorder and status epilepticus treatment. As a majority-owned subsidiary of SciSparc Ltd., Neurothera Labs operates through strategic collaborations and innovative therapeutic combinations. The company also maintains interests in complementary business segments, including a subsidiary focused on hemp seed sales. Through ongoing clinical development initiatives and exploration of advanced analytical technologies, Neurothera Labs seeks to address significant unmet medical needs in neurology and psychiatry, positioning itself within the broader biotech and pharmaceutical research sector.